The Maker of Prozac Just Bet $2.8 Billion on a Psychedelic Depression Drug
Eli Lilly is acquiring AtaiBeckley and its intranasal 5-MeO-DMT depression drug for up to $3.8B — the largest psychedelic acquisition yet. Here's what it means.
Why did the maker of Prozac bet $2.8 billion on a psychedelic depression drug?
Because the antidepressant franchise is aging and the evidence for psychedelic-assisted treatment of depression has become hard to ignore: three of the largest companies in medicine made nine- and ten-figure psychedelic bets within a year. For patients it signals where treatment is heading, not a product available today.
The maker of Prozac just bet $2.8 billion on a psychedelic.
Eli Lilly — the company that defined the antidepressant era — is acquiring AtaiBeckley and its intranasal 5-MeO-DMT program. It is the largest psychedelic acquisition in history, and it says something the research has been signaling for years.
Pharma is buying into psychedelics — fast.
Lilly’s move isn’t an outlier. Three of the largest players in medicine have made nine- and ten-figure psychedelic bets in the space of a year.
Why this is a watershed — not a finished story.
- BPL-003 is still investigational — not FDA-approved, and not available to patients today
- Phase 2b is promising, but a larger Phase 3 program still lies ahead
- An acquisition is a bet on the future, not proof of a finished treatment
- 5-MeO-DMT carries real risks and belongs only in carefully screened, supervised settings
A single-dose depression drug.
BPL-003 is an intranasal form of 5-MeO-DMT built around a striking operational profile: a fast onset, roughly a 90-minute in-clinic visit, and effects that held through eight weeks from one dose.
In a Phase 2b trial of 193 patients across six countries, a single 8 mg dose cut depression scores far more than a low-dose control — a statistically significant difference, with improvement appearing within 24 hours.
Exciting headline — here’s what’s actually available today.
BPL-003 isn’t available to patients yet. If you’re struggling now, these paths are real and available while the science catches up.
Ketamine & Spravato
The one rapid-acting option you can access today for treatment-resistant depression.
Explore ketamine →
Supervised settings abroad5-MeO-DMT today
The compound at the center of the deal — where it’s used now, and the real risks to weigh.
Explore 5-MeO-DMT →
Why a single-dose model is worth billions.
Fast onset
Symptom improvement appearing within 24 hours of a single dose.
~90-minute visit
An in-clinic experience short enough to fit a real-world treatment day.
Durable
Effects sustained through eight weeks in the Phase 2b data.
One dose
A model built around a single administration, not a daily pill.
What the deal means for you right now
A signal, not a shortcut
For patients, the near-term answer is simple: this is a signal, not a shortcut. A major pharmaceutical company backing psychedelic-adjacent research points to a field maturing toward regulated, standardized options — but the treatments involved are still investigational and not something you can ask your doctor for today. It’s a reason for cautious optimism and a good moment to understand your current, real options. If you’re weighing what’s available now, that’s a conversation we’re glad to have: (866) 435-7057.
Frequently asked
Who did Eli Lilly acquire, and for how much?
Eli Lilly agreed on July 16, 2026 to acquire AtaiBeckley for $2.8 billion up front ($6.75 per share in cash), with milestone payments bringing the potential total to $3.8 billion. The acquisition is expected to close in the third quarter of 2026.
What is BPL-003?
BPL-003 is an intranasal formulation of 5-MeO-DMT, a compound in the DMT family, being developed for treatment-resistant depression. It is entering Phase 3 clinical trials and is not FDA-approved.
What does the trial data show so far?
In a Phase 2b trial of 193 patients, a single 8 mg dose of BPL-003 reduced depression scores on the MADRS scale by 12.1 points at the Day 29 primary endpoint, compared with 5.8 for the low-dose control, a statistically significant result, with effects seen within 24 hours and sustained through eight weeks (atai/Beckley Phase 2b topline, 2025). These are mid-stage results; Phase 3 is the confirmatory test still ahead.
Is DMT an approved treatment for depression?
No. 5-MeO-DMT and related compounds are investigational and remain Schedule I controlled substances under U.S. federal law. They are being studied in clinical trials but are not approved by the FDA for depression or any other condition.
Why is a deal like this significant?
It is the largest psychedelic acquisition to date and signals that a major pharmaceutical company expects these compounds to reach FDA approval and be rescheduled. It reflects industry confidence in the direction of depression treatment, following comparable moves by Otsuka and AbbVie.
What depression treatments are actually available now?
Conventional antidepressants remain the standard of care, and esketamine (Spravato) is FDA-approved for treatment-resistant depression. Psychedelic programs like BPL-003 are still in clinical development.
You have real options right now.
Talk with an advisor about the rapid-acting depression treatments that are available today — and which fit your situation. Honest guidance, verified providers, at your pace.
Related on this site: the antidepressant gap · depression · psilocybin therapy · psychedelic therapy options · what we do
Sources and further reading
- NEJM (2021): psilocybin versus escitalopram for depression — randomised, n=59
Speak with an advisor.
A confidential conversation about your situation and the options actually worth considering — from people who visit every provider they recommend.